BCL2L2-PABPN1
ENSG00000258643
Target class
Other cytosolic protein
Chromosome
14
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- BCL2L2-PABPN1
- Gene name
- BCL2L2-PABPN1 readthrough
- Gene symbol
- BCL2L2-PABPN1
- Protein name
- Bcl-2-like protein 2 (Bcl2-L-2) (Apoptosis regulator Bcl-W)
- Gene biotype
- Protein coding
- Target class
- Other cytosolic protein
- Target type
- Human gene
- Tissues expressed in
- 47
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 27.04
- Tissue specificity (Gini)
- 0.425
- Tissue specificity (tau)
- 0.857
- KEGG gene identifiers
- hsa:599
- Protein interaction confidence
- 0.9535
- Protein interaction partners
- 2
- End position
- 23326175
- Start position
- 23306833
- Chromosome
- 14
- Strand
- Forward
- Ensembl gene ID
- ENSG00000258643
- HGNC ID
- HGNC:42959
- NCBI Gene ID
- 100529063
- UniProt ID
- Q92843
- Mitochondrion membrane
- Peripheral membrane protein . Note=Loosely associated with the mitochondrial membrane in healthy cells. During apoptosis, tightly bound to the membrane.
- PubMed 11423909
- PubMed 12952938
- Tissue specificity (tau)
- 0.856725
- Expression inequality (Gini)
- 0.425064
Expression in transcripts per million
- Testis
- 27.04
- Cells - Cultured fibroblasts
- 14.96
- Skin - Not Sun Exposed (Suprapubic)
- 9.18
- Skin - Sun Exposed (Lower leg)
- 9.06
- Adrenal Gland
- 8.59
Expression in transcripts per million
- Testis27.04
- Cells - Cultured fibroblasts14.96
- Skin - Not Sun Exposed (Suprapubic)9.18
- Skin - Sun Exposed (Lower leg)9.06
- Adrenal Gland8.59
- Stomach7.35
- Esophagus - Mucosa7.26
- Fallopian Tube7.05
- Small Intestine - Terminal Ileum6.64
- Prostate6.07
- Minor Salivary Gland5.96
- Pituitary5.85
- Thyroid5.71
- Colon - Transverse5.33
- Vagina5.13
- Adipose - Subcutaneous5.13
- Nerve - Tibial4.77
- Adipose - Visceral (Omentum)4.65
- Lung4.64
- Cervix - Ectocervix4.64
- Breast - Mammary Tissue4.51
- Bladder4.48
- Ovary4.23
- Esophagus - Gastroesophageal Junction3.79
- Esophagus - Muscularis3.59
And 29 more, listed on the interactive page.
- GO:0007283
- GO:0042981
- GO:0043066
- GO:0005739
- GO:0097136
- GO:0005515
- GO:0042802
- GO:0097718
Related records
Trials (756)
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
- a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
- A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
- A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
- A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
- A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Drugs (5)
- Navitoclax Apoptosis regulator Bcl-W inhibitor
- Navitoclax dihydrochloride Apoptosis regulator Bcl-W inhibitor
- Obatoclax Apoptosis regulator Bcl-W inhibitor
- Obatoclax mesylate Apoptosis regulator Bcl-W inhibitor
- Venetoclax